Alignment Healthcare Q3 revenue beats; FY adjusted core profit outlook lowered

By Reuters News


Overview

  • US Medicare Advantage insurer's Q3 revenue grew 36.7% yr/yr, beating analyst expectations

  • Q3 adjusted EBITDA declined 32.8% yr/yr and missed analyst estimates

  • Company lowered full-year adjusted gross profit and adjusted EBITDA guidance due to higher medical costs


Outlook

  • Company expects Q4 revenue of $1.316 bln

  • Alignment Healthcare forecasts 2026 full-year revenue of $5.245 bln

  • Company lowers 2026 full-year adjusted gross profit and adjusted EBITDA guidance


Result Drivers

  • MEMBERSHIP GROWTH - Co said Q3 revenue growth was driven by a 31.2% yr/yr increase in health plan membership

  • HIGHER MEDICAL COSTS - Co attributed lower adjusted gross profit and EBITDA to increased medical costs, including elevated appeals, disputes, catastrophic cases and skilled nursing


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$1.36 bln

$1.31 bln (11 Analysts)

Q3 Net Loss

$8.1 mln

Q3 Adjusted EBITDA

Miss

$21.8 mln

$22.80 mln (13 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the managed healthcare peer group is "buy"

  • Wall Street's median 12-month price target for Alignment Healthcare, Inc. is $11.50, about 40.6% above its October 28 closing price of $8.18

  • The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 77 three months ago


Reuters Recommended Reads

  • Oct 27 - Centene Q3 revenue tops estimates on Medicare growth

  • Oct 27 - HCA signals flat 2027 earnings as Medicaid payments drop; shares slide

  • Oct 27 - Universal Health warns of possible impact to annual results from Medicaid changes; Q3 revenue slightly beats


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.